Long-term prognostic factors for PRRT in neuroendocrine tumors

AIM/INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall survival (OS) rates in the prospective phase III study (NETTER...

Descripción completa

Detalles Bibliográficos
Autores principales: Trautwein, Nils Florian, Schwenck, Johannes, Jacoby, Johann, Reischl, Gerald, Fiz, Francesco, Zender, Lars, Dittmann, Helmut, Hinterleitner, Martina, la Fougère, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288842/
https://www.ncbi.nlm.nih.gov/pubmed/37359009
http://dx.doi.org/10.3389/fmed.2023.1169970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288842/
https://www.ncbi.nlm.nih.gov/pubmed/37359009
http://dx.doi.org/10.3389/fmed.2023.1169970

Ejemplares similares